Inclusion Criteria:

- Participation in and completion of stipulated final follow-up periods for study NTI
0302, NTI 0303, or other designated studies.

- Have a Karnofsky Performance of > 50 at Baseline

- Capable of self-administration of subcutaneous injections twice daily or availability
of assistance from caregiver.

- Ability to provide written informed consent or, if unable to provide, have a legal
guardian or representative provide written informed consent.

- For women of childbearing potential: a negative serum pregnancy test at Baseline

Exclusion Criteria:

- Concurrent enrollment in any investigational drug or device study, other than NTI
0302, NTI 0303, or other designated studies.

- Systemic steroid use for any indication other than peritumoral brain edema.

- Use or intended use of dexamethasone as an anti-emetic during study.

- Clinical signs and symptoms of cerebral herniation.

- Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine
metabolic disease which could put the patient at unusual risk during study
participation.

- Confounding previous or concurrent neurological disorders that would interfere with
adequate clinical evaluation.

- Clinically significant head injury or chronic seizure disorder, if the condition
results in functional impairment or is likely to interfere with
evaluations.(Maintenance anticonvulsant therapy is allowed)

- Central nervous system (CNS) infection.

- Pregnancy, breastfeeding and/or refusal to practice birth control while in study, for
women of childbearing potential.